ArticleCancers2019

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility.

Rosalba D'Alessandro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.